Get the Stockscreener App
32.29
7.48%
-2.61
Pre-market:
32.28
-0.010
-0.03%
Moderna Inc stock is traded at $32.29, with a volume of 11.88M.
It is down -7.48% in the last 24 hours and up +36.13% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$34.90
Open:
$34.86
24h Volume:
11.88M
Relative Volume:
1.10
Market Cap:
$12.62B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.6987
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+8.03%
1M Performance:
+36.13%
6M Performance:
+25.79%
1Y Performance:
-18.44%
1-Day Range:
$32.14
$34.97
1-Week Range:
$29.91
$35.90
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
32.29 | 13.64B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.21 | 116.79B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.17 | 81.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.70 | 53.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.95 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.77 | 37.48B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets - ts2.tech
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Moderna: Why I Am Selling The 'Relief Rally' (NASDAQ:MRNA) - Seeking Alpha
Moderna Stock (MRNA) Drops on Dec. 23, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
Moderna (NASDAQ:MRNA) Trading Down 5.8%Here's Why - MarketBeat
Moderna price drops — what’s behind today’s move (December 23) - Traders Union
Moderna CEO Bancel holds expiring stock options, bets on drugmaker's recovery - The Business Journals
Thrivent Financial for Lutherans Has $2.57 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Fayetteville Observer
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Florida Today
Moderna up almost 4%, looking to continue outperformance streak - TradingView — Track All Markets
COVID-19 Vaccine Market set for steady growth to US$ 29.98 - openPR.com
Moderna’s Strategic Moves Aim to Fortify Its Financial Future - AD HOC NEWS
Rivian, Sandisk, And Moderna Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?Affirm Holdings (NASDAQ:AFRM), BioMarin Pharmaceutical (NASDAQ:BMRN), Carnival (NYSE:CCL), Lumentum Holdi - Benzinga
Moderna, Inc. $MRNA Shares Bought by Douglas Lane & Associates LLC - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Daytona Beach News-Journal
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine - Daily Commercial
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025) - ts2.tech
Moderna to Host Investor Event – Analyst Day - The Holland Sentinel
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - Enterprise News
Ideas Watch: How buybacks impact Moderna Inc. stock valueJuly 2025 Levels & Daily Momentum Trading Reports - Улправда
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab - Finviz
CEPI to fund Moderna’s mRNA pandemic flu candidate - The Pharma Letter
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise - simplywall.st
Down 80%, Should You Buy the Dip on Moderna? - Finviz
Inside Biotech: Moderna’s bird flu funding brings pandemic preparedness back into view - Proactive financial news
Moderna gets funding for bird flu shot after HHS ends contract - The Boston Globe
Moderna gets funding for H5 pandemic influenza vaccine - BioPharma Dive
Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding - Yahoo Finance
Moderna, Inc. (MRNA): A Bull Case Theory - Finviz
Moderna, Inc. (MRNA): A bull case theory - MSN
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullbac - GuruFocus
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback - Yahoo Finance
Why Moderna (MRNA) Stock Is Up Today - Finviz
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):